Wall Street Zen upgraded shares of Basel Medical Group (NASDAQ:BMGL – Free Report) to a hold rating in a report issued on Saturday,Wall Street Zen reports.
Separately, Weiss Ratings lowered Basel Medical Group from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, October 23rd. One analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.
Get Our Latest Stock Analysis on BMGL
Basel Medical Group Stock Up 1.9%
Shares of NASDAQ:BMGL opened at $5.29 on Friday. The stock’s 50-day moving average price is $4.37 and its 200-day moving average price is $6.40. Basel Medical Group has a 12-month low of $2.56 and a 12-month high of $18.48.
Basel Medical Group (NASDAQ:BMGL – Get Free Report) last released its quarterly earnings data on Friday, October 30th. The company reported ($0.31) EPS for the quarter. The firm had revenue of $3.14 million during the quarter.
Basel Medical Group Company Profile
Basel Medical Group Ltd. is an investment holding company, which engages in providing orthopedic surgeries, medical care, and diagnosis services. Its services include orthopedic surgeries, medical care, rehabilitative therapy, physiotherapy, non-surgical treatments, medical diagnosis, magnetic resonance imaging, general surgery, x-ray, lump removal, sports medicine, and total hip replacement. The company was founded by Man Hing Yip on August 10, 2023 and is headquartered in Singapore.
Recommended Stories
- Five stocks we like better than Basel Medical Group
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Basel Medical Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basel Medical Group and related companies with MarketBeat.com's FREE daily email newsletter.
